Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees

Beate

Beate Bleeker, Munich DE

Patent application number	Description	Published
20090246571	DETERMINATION OF THE LAMBDA VALUE OF REFORMATE WITH THE AID OF A FUEL CELL - The invention relates to a process for determining the lambda value (λ	10-01-2009
20090297898	REFORMING SYSTEM, METHOD FOR OPERATING A REFORMING SYSTEM AND FUEL CELL SYSTEM - The invention relates to a reformer system for generating a hydrogen-rich reformate comprising a reformer to which fuel and an oxidising agent can be supplied. According to the invention it is contemplated that the fuel supplied to the reformer is at least partly coolable by a fluid having other functions in addition to the function of cooling the fuel in the reformer system or a parent system into which the reformer system is integrated. The invention further relates to a method for generating a hydrogen-rich reformate as well as a fuel cell system comprising a reformer system according to the invention.	12-03-2009
20100212977	REFORMER FOR A FUEL CELL SYSTEM AND METHOD FOR OPERATING SAID REFORMER - The invention relates to a reformer (	08-26-2010
20100212991	FUEL CELL SYSTEM COMPRISING A REFORMER AND AN AFTERBURNER - The invention relates to a fuel cell system (	08-26-2010
20110117464	FUEL CELL SYSTEM AND METHOD FOR INFLUENCING THE THERMAL BALANCE OF A FUEL CELL SYSTEM - The invention relates to a fuel cells system (	05-19-2011

Beate Bleeker, München DE

Patent application number	Description	Published
20090155653	FUEL CELL SYSTEM - The invention relates to a fuel cell system comprising a reformer and an afterburner each for reacting at least fuel and an oxidant; and a fuel feeder for supplying the reformer and the afterburner with fuel. It is provided for to particular advantage that at least one flow control valve for controlling the fuel supply is included upstream of at least the reformer or the afterburner. The invention relates furthermore to a motor vehicle having one such fuel cell system.	06-18-2009

Beate Bleeker, München DE

Patent application number	Description	Published
20090155653	FUEL CELL SYSTEM - The invention relates to a fuel cell system comprising a reformer and an afterburner each for reacting at least fuel and an oxidant; and a fuel feeder for supplying the reformer and the afterburner with fuel. It is provided for to particular advantage that at least one flow control valve for controlling the fuel supply is included upstream of at least the reformer or the afterburner. The invention relates furthermore to a motor vehicle having one such fuel cell system.	06-18-2009

Beate Buerglen, Jena DE

Patent application number	Description	Published
20090117183	ORAL CONTRACEPTIVE CONTAINING A GESTAGEN AND AN ESTROGEN COMBINED WITH PHARMACEUTICALLY ACCEPTABLE AUXILIARY AGENTS AND/OR EXCIPIENTS, BUT NOT CONTAINING LACTOSE, AND METHOD OF MAKING SAME - The method produces a lactose-free oral contraceptive composition containing a combination of a gestagen and an estrogen together with one or more pharmaceutically acceptable auxiliary agents and/or excipients. The contraceptive composition is a tablet, powder, or capsule that contains the gestagen and estrogen, filler material such as microcrystalline cellulose and a binder such as hydroxypropylcellulose, but no lactose. Preferably the gestagen is dienogest, chlormadinone acetate, or levonorgestrel and the estrogen is ethinylestradiol, 17β-estradiol, or estradiol valerate. A method is provided for improving the prophylaxis of lactose intolerance in women taking oral contraceptives. The oral contraceptive preparations for a standard 28-day cycle or for long-term use contain at least 21 daily dose units of the gestagen and the estrogen in a low-dosage but without lactose and at most 7 daily dose units containing no active ingredient or a placebo.	05-07-2009
20090117184	Use of a gestagen in combination with an estrogen and one or more pharmaceutically acceptable auxiliary agents/excipients for lactose-free oral contraception - Gestagens, preferably dienogest, chlormadinone acetate or levonorgestrel, in combination with estrogens, for example ethinylestradiol, 17β-estradiol or estradiol valerate, and one or more pharmaceutically acceptable auxiliary agents/excipients provide lactose-free oral contraception.	05-07-2009

Beate Celmerowski, Spaichingen DE

Patent application number	Description	Published
20080230423	Holding device for an implant - In order to improve a holding device for an implant, comprising a first connecting device for releasably connecting the holding device and the implant, such that very small implants, in particular, are easy to handle, it is suggested that the holding device have a second connecting device for releasably connecting the holding device and a storage unit.	09-25-2008

Beate Diefenbach-Streiber, Windach DE

Patent application number	Description	Published
20090130113	Compositions and methods for use for antibodies against sclerostin - The present invention relates to antibodies against sclerostin and compositions and methods of use for said antibodies to treat disease related to bone abnormalities such as osteoporosis. An embodiment of the invention herein provides an antibody or a functional protein comprising an antigen-binding portion of said antibody for a target in sclerostin polypeptide, characterized in that the antibody or functional protein specifically binds to sclerostin polypeptide and can increase at least one of bone formation, bone mineral density, bone mineral content, bone mass, bone quality and bone strength in a mammal.	05-21-2009
20100034809	Compositions and Methods for Antibodies Targeting Complement Protein C5 - The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.	02-11-2010
20110052592	Compositions and Methods for Use for Antibodies Against Sclerostin - The present invention relates to antibodies against sclerostin and compositions and methods of use for said antibodies to treat a pathological disorder that is mediated by sclerostin or disease related to bone abnormalities such as osteoporosis.	03-03-2011

Beate Frohling, Steinen DE

Patent application number	Description	Published
20080295260	Disulfide Dyes, Composition Comprising them and Method of Dyeing Hair - Formula (I) wherein R	12-04-2008

Beate Fröhling, Neustadt DE

Patent application number	Description	Published
20120012128	HAIR DYEING COMPOSITION - Disclosed is a hair dyeing composition comprising (a) a dye of formula (1); (b) at least one dye selected from the compounds of formulae (2); wherein D is the radical of a diazo component of the formula (2a); K is the radical of a coupling component selected from aniline derivatives; phenol derivatives; and a radical of a heterocyclic coupling component; X is O—; —S—; or N(R	01-19-2012

Beate Fröhling, Grenzach-Wyhlen DE

Patent application number	Description	Published
20090217465	Process for Hair Dyeing Comprising Application of Composite Pigment - Disclosed is a process for dyeing of keratin-containing fibers comprising treating the fibers with at least one functionalized particle comprising on the surface an organic chromophore which is bound via a bridge member, wherein the particles are based on SiO	09-03-2009
20090255063	Polymeric hair dyes - Disclosed are polymeric dyes of formula (1a); (1b); or (1c); wherein A and B, independently from each other represent a polymer backbone; X	10-15-2009
20090293208	Cationic oligomeric azo dyes - Disclosed are oligomeric cationic azo dyes of formula (I), wherein their salts, isomers, hydrates and other solvates, wherein R	12-03-2009
20090300855	Pyrido Thiazinium Dyes - Disclosed is a method of dyeing keratin-containing fibers comprising treating the fiber with at least one compound of formula (1), wherein R	12-10-2009
20090300857	DYES CONTAINING A THIOL GROUP - Disclosed are thiol dyes of formula (1), wherein R	12-10-2009
20100000028	Styryl sulfide dyes - Disclosed are styryl sulfide dyes of formula (1), wherein R	01-07-2010
20100000029	THIOL DERIVATIVE DYES - Disclosed are thiol dyes of formula (1) wherein L1 is hydrogen; C	01-07-2010

Beate Grzondziel, Gebenstorf CH

Patent application number	Description	Published
20090126190	METHOD FOR PRODUCING A TURBINE CASING - A method for producing a turbine casing for a rotating machine is provided. The casing is manufactured by a casting process, and is cast in two casing halves which are separated by a parting plane which passes axially through the turbine casing. Each casing half is first cast in one piece in each case, and each casing half is separated into at least two casing sections which are joined together for forming a casing half in each case.	05-21-2009

Beate Illek, Albany, CA US

Patent application number	Description	Published
20100286256	COMPOSITIONS AND METHODS FOR THERAPY FOR DISEASES CHARACTERIZED BY DEFECTIVE CHLORIDE TRANSPORT - Compositions and methods for therapy of cystic fibrosis, asthma, and other conditions characterized by defective chloride transport are provided. The compositions comprise one or more compounds such as flavones and/or isoflavones, ascorbate and/or derivatives thereof capable of stimulating chloride transport in epithelial tissues. Therapeutic methods involve the administration (e.g., orally or via inhalation) of such compositions to a patient afflicted with cystic fibrosis, asthma, and/or another condition responsive to stimulation of chloride transport.	11-11-2010

Beate Kälz, Steinbrunn AT

Patent application number	Description	Published
20090253743	COMPOSITIONS OF TOLPERISONE - The present disclosure is directed to methods for providing tolperisone having extremely low levels of 4-MMPPO (2-methyl-1-(4-methylphenyl)-propenone), as well as related compositions. The invention further relates to methods of treating a subject with tolperisone under conditions that limit exposure of the subject to tolerable levels of 4-MMPPO, among other features.	10-08-2009
20090326219	PROCESS FOR MANUFACTURING EXTREMELY PURE BENZAZEPINE DERIVATIVES - A process for the production of extremely pure galanthamine or extremely pure galanthamine derivatives, a start is made from racemic bromine narwedine, which is debrominated under palladium catalysis. In this case, the working-up of the reaction mixture, which is carried out in the presence of oxygen or peroxides so that the palladium catalyst in an insoluble form is converted into an easily separable form, is essential. The further reaction is carried out by reduction of enantiomer-pure narwedine to form enantiomer-pure galanthamine, whereby it is then alkylated or dealkylated so that a corresponding substitution on the ring-nitrogen atom is achieved. By further purification, such as recrystallization, residual portions of palladium of below 5 ppm are achieved, so that direct use as a pharmaceutical raw material is made possible.	12-31-2009
20100150995	PROCESS FOR THE PRODUCTION OF HIGH-PURITY 2,4'-DIMETHYL-3-PIPERIDINO-PROPIOPHENONE (TOLPERISONE), PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THE LATTER, AS WELL AS ACTIVE INGREDIENT FORMULATIONS THAT CONTAIN TOLPERISONE - The invention relates to a method for producing highly pure 2,4′-dimethyl-3-piperidino-propiophenone (tolperisone) (formula I) and the pharmaceutically acceptable salts, hydrochlorides, and hydrates thereof. The method allows the content of the undesired byproduct 2-methyl-1-(4-methylphenyl) propenone (4-MMPPO) to be kept significantly lower than in previously known methods. The invention further relates to active substance formulations which contain tolperisone and are suitable, among other things, for producing combination preparations used for treating patients suffering from Alzheimer's disease. The invention also relates to topical formulations, controlled release (CR) formulations, and transdermal therapeutic systems, such as active substance patches, which contain less than 50 ppm, preferably less than 10 ppm, more preferably less than 7 ppm, and most preferably less than 3 ppm or 0 ppm (i.e. less than the detectable amount) of the undesired byproduct 2-methyl-1-(4-methylphenyl) propenone (4-MMPPO) in relation to 100 percent by weight of active substance.	06-17-2010
20100249423	TOLPERISONE CONTROLLED RELEASE TABLET - A GRDDS (Gastro Retentive Drug Delivery System) containing tolperisone and having a 2-methyl-1-(4-methylphenyl)-propenone (4-MMPPO) fraction of less than 1.5 ppm for the extended release of the active substance tolperisone while avoiding the formation of 4-MMPPO in the gastrointestinal tract.	09-30-2010

Beate Kälz, Steinbrunn AT

Patent application number	Description	Published
20090326219	PROCESS FOR MANUFACTURING EXTREMELY PURE BENZAZEPINE DERIVATIVES - A process for the production of extremely pure galanthamine or extremely pure galanthamine derivatives, a start is made from racemic bromine narwedine, which is debrominated under palladium catalysis. In this case, the working-up of the reaction mixture, which is carried out in the presence of oxygen or peroxides so that the palladium catalyst in an insoluble form is converted into an easily separable form, is essential. The further reaction is carried out by reduction of enantiomer-pure narwedine to form enantiomer-pure galanthamine, whereby it is then alkylated or dealkylated so that a corresponding substitution on the ring-nitrogen atom is achieved. By further purification, such as recrystallization, residual portions of palladium of below 5 ppm are achieved, so that direct use as a pharmaceutical raw material is made possible.	12-31-2009
20100249423	TOLPERISONE CONTROLLED RELEASE TABLET - A GRDDS (Gastro Retentive Drug Delivery System) containing tolperisone and having a 2-methyl-1-(4-methylphenyl)-propenone (4-MMPPO) fraction of less than 1.5 ppm for the extended release of the active substance tolperisone while avoiding the formation of 4-MMPPO in the gastrointestinal tract.	09-30-2010

Beate Kamlage, Berlin DE

Patent application number	Description	Published
20080234945	Means and Methods for Analyzing a Sample by Means of Chromatography-Mass Spectrometry - The present invention relates to a method for analyzing at least one test sample, wherein said test sample comprises at least one compound, said method comprising the steps of: a) providing at least one test sample comprising at least one compound; b) determining said at least one compound in said test sample whereby raw results are generated; and c) analyzing the raw results obtained in step b), wherein the analysis of said at least one test sample is accompanied by an analysis of at least one reference sample; and wherein the test sample and the reference sample are analyzed in an identical sequence in each step of the method. Moreover, the present invention further encompasses a system for carrying out said method comprising operatively linked to each other: (a) means for determining a compound; (b) means for monitoring process parameters, (c) means for analyzing raw results obtained from the means according to (a), wherein said means for analyzing raw results comprise: (i) a first database comprising raw results received from the means according to (a); (ii) a second database comprising monitored process parameters received from the means according to (b); (iii) a third database comprising rules for evaluating the raw results; and (iv) a fourth database comprising allocated results of identified compounds; wherein at least the second, third and fourth database are operatively linked to the first database.	09-25-2008
20090300794	Manipulation Of The Nitrogen Metabolism - The present invention relates to the manipulation of the nitrogen metabolism in photosynthetic active organisms, preferably in plants. In particular, the present invention relates to a process for the enhanced nitrogen assimilation, accumulation and/or utilization and/or for the increased total nitrogen content in a photosynthetic active organism.	12-03-2009
20100031380	IDENTIFICATION OF CHILLING-RESISTANT PLANTS - A process for identifying whether plant is resistant to chilling comprises cultivating the plant at a reduced temperature for a time period selected from short term and medium term; harvesting a tissue sample of the plant; measuring concentration of at least one metabolite in the tissue sample of the plant; comparing the measured concentration with the concentration of the same metabolite in a tissue sample harvested from a reference plant or a plant of the same species after cultivation at a reference temperature; and optionally, repeating the process of foregoing steps but cultivating the plant at a reduced temperature for a time period selected from short term and medium term and not previously used; wherein resistance to chilling is indicated by one or more of the effects on metabolites listed in Table 2 or Table 4.	02-04-2010
20110035841	Lipid Metabolism Proteins, Combinations of Lipid Metabolism Proteins and Uses Thereof - Described herein are inventions in the field of genetic engineering of plants, including combinations of polynucleotides encoding LMPs to improve agronomic, horticultural, and quality traits. This invention also relates to the combination of polynucleotides encoding proteins that are related to the presence of seed storage compounds in plants. More specifically, the present invention relates to LMP polynucleotides encoding lipid metabolism proteins (LMP) and the use of these combinations of these sequences, their order and direction in the combination, and the regulatory elements used to control expression and transcript termination in these combinations in transgenic plants. In particular, the invention is directed to methods for manipulating fatty acid-related compounds and for increasing oil and starch levels and altering the fatty acid composition in plants and seeds. The invention further relates to methods of using these novel combinations of polypeptides to stimulate plant growth, and/or root growth and/or to increase yield and/or composition of seed storage compounds.	02-10-2011
20110113863	MEANS AND METHODS DIAGNOSING GASTRIC BYPASS AND CONDITIONS RELATED THERETO - The present invention relates to the field of diagnostic measures. Specifically, it contemplates a method for assessing whether gastric bypass therapy was successful in a subject, a method of predicting whether gastric bypass therapy will be beneficial for a subject in need thereof, and a method of diagnosing whether a supportive therapy accompanying gastric bypass has beneficial effects on a subject in need thereof. Further provided are diagnostic methods for diabetes and body lean mass. Furthermore, the invention relates to a method for identifying a treatment against diabetes and/or obesity.	05-19-2011
20110252509	Method for Producing a Transgenic Cell with Increased Gamma-Aminobutyric Acid (Gaba) Content - This invention relates generally to a method for producing a transgenic cell with increased gamma-aminobutyric acid (GABA) content as compared to a corresponding non-transformed wild type cell.	10-13-2011
20120005777	Process for the Production of Fine Chemicals - The present invention relates to a process for the production of fine chemicals in a microorganism, a plant cell, a plant, a plant tissue or parts thereof. The invention furthermore relates to nucleic acid molecules, polypeptides, nucleic acid constructs, vectors, antisense molecules, antibodies, host cells, plant tissue, propagtion material, harvested material, plants, microorganisms as well as agricultural compositions and to their use.	01-05-2012

Beate Kätz, Steinbrunnd AT

Patent application number	Description	Published
20100324090	COMPOSITIONS OF TOLPERISONE - The present disclosure is directed to methods for providing tolperisone having extremely low levels of 4-MMPPO (2-methyl-1-(4-methylphenyl)-propenone), as well as related compositions. The invention further relates to methods of treating a subject with tolperisone under conditions that limit exposure of the subject to tolerable levels of 4-MMPPO, among other features.	12-23-2010

Beate Kätz, Steinbrunnd AT

Patent application number	Description	Published
20100324090	COMPOSITIONS OF TOLPERISONE - The present disclosure is directed to methods for providing tolperisone having extremely low levels of 4-MMPPO (2-methyl-1-(4-methylphenyl)-propenone), as well as related compositions. The invention further relates to methods of treating a subject with tolperisone under conditions that limit exposure of the subject to tolerable levels of 4-MMPPO, among other features.	12-23-2010

Beate Katzschner, Reinhardtsdorf DE

Patent application number	Description	Published
20090124488	Substrate with Spatially Selective Metal Coating, Method for Production and Use Thereof - A substrate with spatially selective metal coating is produced by first applying biological templates onto parts of the surface of the substrate and applying a metal coating only once the biological templates have been deposited on the substrate. The biological templates are for example surface layer proteins (S-layer) and the metal coating is a noble metal coating. The substrates with spatially selective metal coating are used in catalysts or solid-state electrolyte sensors.	05-14-2009

Beate Kehrel, Muenster DE

Patent application number	Description	Published
20090036360	MEDICAMENT CONTAINING ACTIVATED ANTITHROMBIN III - The invention concerns the use of antithrombin III with a modified conformation which is referred to as activated antithrombin III (IDAAT=immune defence activated antithrombin) as a medicament.	02-05-2009

Beate Kinga Jaszczuk, Munster DE

Patent application number	Description	Published
20110087012	NUCLEIC ACID MOLECULES CODING FOR A PROTEIN WITH DEACETYLASE ACTIVITY, SAID PROTEIN, AND METHOD FOR THE PRODUCTION OF CHITOSAN - The invention relates to nucleic acid molecules selected from the group comprising: a) nucleic acid molecules that code for a form of the polypeptide with the derived amino acid sequence according to SEQ ID No. 3, said polypeptide having a deacetylase activity; b) nucleic acid molecules that comprise the nucleotide sequence according to SEQ ID No. 1 or SEQ ID No. 2 and that code for one form of said polypeptide; c) nucleic acid molecules that code for a fragment or a derivative of a polypeptide that is coded by a nucleic acid molecule according to a) or b), wherein one or more amino acid groups are conservatively substituted in said derivative as compared to said polypeptide, and wherein said fragment or derivative has a deacetylase activity; d) nucleic acid molecules that have a sequence identity of at least 95% with a nucleic acid molecule according to a) to c), and that code for a polypeptide with deacetylase activity; e) nucleic acid molecules that have a sequence identity of at least 70% with a nucleic acid molecule according to a) to c) and that code for a polypeptide with deacetylase activity; f) or the complementary string of a nucleic acid molecule according to a) to e).	04-14-2011

Beate Koksch, Berlin DE

Patent application number	Description	Published
20120016103	PEPSTATIN A DERIVATIVES - The invention relates to a compound having a structure according to the general formula P3-P2-P1-P1′-P2′ (I), wherein residues P3, P2, P1, P1′ and P2′ are specifically defined and may be, e.g., certain amino acid residues. The invention further relates to the use of said compound and to a method for synthesizing a peptide.	01-19-2012

Beate Koschorreck, Schriesheim DE

Patent application number	Description	Published
20100172798	METHOD FOR THE PRODUCTION OF AN ANALYTICAL ELEMENT - A method is provided for producing an analytical element comprising at least one test field for analyzing a liquid sample, wherein provision is made for a carrier on which a polymer fabric is arranged. At least one portion of the polymer fabric is irradiated with UV laser light and thereby hydrophobized.	07-08-2010

Beate Langenhan, Niederkrüchten DE

Patent application number	Description	Published
20080317589	Compressor Housing for Use at Low Temperatures - The invention relates to a turbo machine comprising a housing. Said turbo machine is designed especially as a turbo compressor for use at low temperatures, the housing preferably being made of a cold-resistant material that has a martensitic structure.	12-25-2008
20090242084	Method for Producing a Shaft for Compressors - A method for the production of steels is provided. A heat treatment is carried out, in which the steel is hardened in water twice at different high temperatures, and subsequently subjected to an annealing treatment. It has been shown that the steel 26NiCrMoV14-5 has a high subzero toughness. In one aspect, the steel is usable down to a temperature of at least minus 170° C.	10-01-2009

Beate Langenhan, Niederkrüchten DE

Patent application number	Description	Published
20090242084	Method for Producing a Shaft for Compressors - A method for the production of steels is provided. A heat treatment is carried out, in which the steel is hardened in water twice at different high temperatures, and subsequently subjected to an annealing treatment. It has been shown that the steel 26NiCrMoV14-5 has a high subzero toughness. In one aspect, the steel is usable down to a temperature of at least minus 170° C.	10-01-2009

Beate Maassen-Francke, Oelde DE

Patent application number	Description	Published
20090013934	AUTOMATIC SEPARATION OF ANIMAL MILK - The invention relates to, inter alia, a method for determining a modified waiting period for a milk-producing animal treated with a veterinary medicament. According to said method, at least one quantity of milk is determined during at least one time interval following the administration of the veterinary medicament, said interval being shorter than a pre-determined waiting period. A milk yield for the waiting period is predicted from the quantity of milk. A modified waiting period is determined on the basis of the predicted milk yield and a milk yield for the waiting period pre-determined by the veterinary medicament. The inventive method enables MRL values to be surely and reliably maintained, such that milk is separated according to the modified waiting period.	01-15-2009

Beate Muller, Hanner DE

Patent application number	Description	Published
20080287501	THERAPEUTIC USES OF AN INSULIN SECRETION ENHANCER - The invention relates to the use of a hypolipidemic agent or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prevention or delay of the progression to overt diabetes, especially type 2, prevention or reduction of microvascular complications (eg, retinopathy, neurophathy, nephropathy), prevention or reduction of excessive cardiovascular morbidity (eg, myocardial infarction, arterial occlusive disease, atherosclerosis and stroke) and cardiovascular mortality, prevention of cancer and reduction of cancer deaths. Additionally, the invention relates to the use of a treatment for diseases and conditions that are associated with IGM, IGT or IFG.	11-20-2008

Beate Nothhelfer-Kolb, Untrhaching DE

Patent application number	Description	Published
20090235225	Rule based instantiation of software- and system development processes - A method, system and a computer readable medium for performing a rule based instantiation of a generic software and/or system development process to provide a project specific implemented instantiated process. The proposed approach provides a gradual way to provide an implemented instantiated process adapted to project specific needs by using a staggered instantiation mode. The approach distinguishes between high level instantiation and detailed instantiation depending on the nature of the instantiation operation. The approach is flexibly applicable to software and systems development processes and the set of instantiation operations is extendable.	09-17-2009

Beate Pscheidt, Hart-Purgstall AT

Patent application number	Description	Published
20100143986	R-HNL RANDOM VARIANTS AND THEIR USE FOR PREPARING OPTICALLY PURE, STERICALLY HINDERED CYANOHYDRINS - The invention relates to R-hydroxynitrile lyases with improved substrate acceptance, increased activity and increased selectivity, obtainable by introducing random mutations with the aid of random mutagenesis and/or saturation mutagenesis techniques, identifying by means of screening or selection and, where appropriate, subsequently combining advantageous mutations, and to the use thereof.	06-10-2010

Beate Sczekalla, Halle DE

Patent application number	Description	Published
20110076502	PURIFIED ACETYLATED DERIVATIVES OF CASTOR OIL AND COMPOSTIONS INCLUDING SAME - The present disclosure is directed to a single phase acetylated castor component (SP-ACC). An acetylated castor component is purified to produce the SP-ACC which contains a reduced amount of, or no, insoluble component(s) therein. The SP-ACC enhances the performance and properties of plasticizers of which it is a component.	03-31-2011

Beate Stern, Beate NO

Patent application number	Description	Published
20110136236	GENETICALLY MODIFIED EUKARYOTIC CELLS - The invention relates to a method of producing genetically modified eukaryotic cells with optimised growth characteristics wherein a recombinant first nucleotide sequence has been integrated into a desired position in the genome. The sequence contains at least one gene encoding a plasma membrane protein with either toxin-receptor or toxic properties and allowing for surface expression based cell sorting to identify a suitable genomic integration locus. The invention also relates to a second exogenous nucleotide sequence containing at least one protein of interest as well as a vector, which aids in the site specific exchange of the first with the second nucleotide sequence. Efficient exchange is achieved by a stringent selection strategy that will kill all cells still expressing the plasma membrane protein.	06-09-2011

Beate Treffler, Neusaess DE

Patent application number	Description	Published
20110275837	Waxes Having High Polarity and the Use Thereof as Slip Agents for Chlorine-Containing Thermoplastics - Copolymer waxes, characterized by an iodine number of <15, preferably <13 g of iodine/100 g, a viscosity at 100° C. ranging between 200 to 4000 mPa*s, a dropping point ranging between 60 to 90° C., a ram penetration hardness ranging between 200 to 600 bar, an acid number ranging between 60 to 100 mg of KOH/g, and an iodine color number<10. The copolymer waxes according to the invention are suited in particular as processing aids for PVC, polyvinylidene chloride and copolymers of vinyl chloride, having up to 30% by weight comonomers.	11-10-2011

Beate Von Teichmann, Annlin ZA

Patent application number	Description	Published
20110091500	Inactivated Live-Attenuated Bluetongue Virus Vaccine - The invention describes the preparation of an inactivated bluetongue virus (BTV) composition, and in particular a vaccine, using an attenuated live BTV vaccine strain as masterseed. The vaccine can be administered to an animal to prevent bluetongue disease by eliciting an immune response against the bluetongue virus serotype(s) included in the composition.	04-21-2011

Beate Walter, Stutensee DE

Patent application number	Description	Published
20100070016	STENT DEVICE ADHESIVELY BONDED TO A STENT DEVICE PUSHER - A stent device delivery system, comprising a stent device pusher, a radially expandable stent device and an outer sheath. A tacky material provides a tackiness between the stent device pusher and an inner surface of the stent device. The tacky material is distributed along the length of the stent device. The tacky material serves to resist axial movement of the stent device relative to the stent device pusher as the outer sheath slides axially over the stent device, yet allows the stent device to peel from the tacky material and expand to a radially expanded state as the outer sheath slides axially over the stent device to release the stent device. The tacky material may be compressible such that the stent device is embedded in the compressible tacky material.	03-18-2010
20100179637	TRANS-LUMINAL SURGICAL DEVICE - A device for trans-luminal delivery of a self-expanding stent or other surgical device and which is designed for rapid exchange over a guidewire has a guidewire lumen that adjacent its proximal exit port lies side-by-side with the line of the shaft of the device. A sleeve which surrounds and confines the stent has a proximal end that is shaped around the guidewire exit port to show in profile a shape reminiscent of the nose of a dolphin. In preferred embodiments, the sleeve also has a tapered distal tip that is withdrawn proximally over the length of the stent to release it, progressively, from its distal end. The configuration delivers simplicity of design, enhanced performance and reliability in use.	07-15-2010

Beate Ziak-Beyerlein, Numberg DE

Patent application number	Description	Published
20100203286	Structured component, in particular a shielding element in the form of a heat shield - The invention relates to a structured component, in particular a shielding element in the form of a heat shield, comprising a shielding body (	08-12-2010

Beate Zietek-Strietz, Heidelberg DE

Patent application number	Description	Published
20100034650	CENTRIFUGAL PUMP - The invention relates to a centrifugal pump, in particular, a single stage or multi-stage side channel pump in a modular design, wherein the stage or every stage of the pump comprises a preferably divided modular housing with assigned centrifugal impellers, which are designed so as to be self-supporting; and, thus, a pump shaft, which is known in the prior art, is no longer necessary.	02-11-2010

Beate Zika-Beyerlein, Nurnberg DE

Patent application number	Description	Published
20080292832	Structural component in the form of a heat shield - The invention relates to a structural component in the form of a heat shield, consisting of at least two interconnected structural layers, of which one structural layer (	11-27-2008